These are given around multiple drugs, a number one One hour prior to a transplant operation & Cinque farther drugs given at ii week intervals when a transplant. These saturate a receptors & block T cell activation & so halt formation of antibodies against the transplant.

Such as a similar drug basiliximab, daclizumab reduces a incidence & harshness of intense rejection around kidney transplantation while forgoing increasing the incidence of opportunistic infections.

Daclizumab can too become utilized in situ of the calcineurin-inhibitor (cyclosporine or tacrolimus) in a early phase after kidney transplantation whilst the kidney is recovering & vulnerable to calcineurin-inhibitor toxicity. This has been shown to exist as beneficial inside non-heart beating donor kidney transplantation.

In the United Kingdom, the National Institute for Clinical Excellence has recommended its use exist as considered for everthing kidney transplant recipients.